內部人士可能會獲得普通股東無法享受的可觀財務利益。
擬議的交易可能包含限制更優競爭報價的條款。
鼓勵股東與本公司聯繫，討論他們的權利和選擇，且無需支付任何費用或承擔任何義務。我們將以風險代理的方式處理任何事務，您無需承擔我們的法律費用或開支。
, /PRNewswire/ -- Halper Sadeh LLC，一家投資者權益法律事務所，正在調查以下公司是否存在違反聯邦證券法和/或對股東的信託責任的行為，涉及：
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 以每股 41.00 美元現金及一項不可轉讓的或有價值權出售給 Biogen Inc.，該權利允許在滿足某些年度全球淨銷售閾值的情況下，獲得兩筆每股 2.00 美元的付款。如果您是 Apellis 的股東， 請點擊這裏瞭解您的法律權利和選擇。
Centessa Pharmaceuticals plc (NASDAQ: CNTA) 以每股 38.00 美元現金及一項不可轉讓的或有價值權出售給 Eli Lilly and Company，該權利允許持有人在達到某些里程碑的情況下，最多獲得 9.00 美元的總額。如果您是 Centessa 的股東， 請點擊這裏瞭解您的法律權利和選擇。
Kezar Life Sciences, Inc. (NASDAQ: KZR) 以每股 6.955 美元現金及一項不可轉讓的或有價值權出售給 Aurinia Pharmaceuticals Inc.。如果您是 Kezar 的股東， 請點擊這裏瞭解您的法律權利和選擇。
代表股東，Halper Sadeh LLC 可能尋求增加對價、額外披露和信息，或其他救濟和利益。
Halper Sadeh LLC 代表全球的投資者，幫助他們應對證券欺詐和企業不當行為。我們的律師在實施公司改革和為受欺詐投資者追回數百萬美元方面發揮了重要作用。
律師廣告。以往的結果並不保證類似的結果。
聯繫信息：
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
世界貿易中心一號
85 層
紐約，NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
來源 Halper Sadeh LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw"/>

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

Halper Sadeh LLC 正在調查 Apellis Pharmaceuticals (APLS)、Centessa Pharmaceuticals (CNTA) 和 Kezar Life Sciences (KZR) 是否存在違反聯邦證券法和違反信託責任的潛在行為。該公司擔心內部人士可能會在普通股東的利益受損的情況下獲得財務利益，原因是擬議交易條款。鼓勵股東與該公司聯繫，討論他們的權利和選擇，且無需支付費用。調查重點是這些公司向更大公司的銷售，可能會尋求增加對股東的考慮或披露

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
<div class="lb-trans">內部人士可能會獲得普通股東無法享受的可觀財務利益。
</div>The proposed transactions may contain terms that could limit superior competing offers.
<div class="lb-trans">擬議的交易可能包含限制更優競爭報價的條款。
</div>Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
<div class="lb-trans">鼓勵股東與本公司聯繫，討論他們的權利和選擇，且無需支付任何費用或承擔任何義務。我們將以風險代理的方式處理任何事務，您無需承擔我們的法律費用或開支。
</div>, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
<div class="lb-trans">, /PRNewswire/ -- Halper Sadeh LLC，一家投資者權益法律事務所，正在調查以下公司是否存在違反聯邦證券法和/或對股東的信託責任的行為，涉及：
</div>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 以每股 41.00 美元現金及一項不可轉讓的或有價值權出售給 Biogen Inc.，該權利允許在滿足某些年度全球淨銷售閾值的情況下，獲得兩筆每股 2.00 美元的付款。如果您是 Apellis 的股東， 請點擊這裏瞭解您的法律權利和選擇。
</div>Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Centessa Pharmaceuticals plc (NASDAQ: CNTA) 以每股 38.00 美元現金及一項不可轉讓的或有價值權出售給 Eli Lilly and Company，該權利允許持有人在達到某些里程碑的情況下，最多獲得 9.00 美元的總額。如果您是 Centessa 的股東， 請點擊這裏瞭解您的法律權利和選擇。
</div>Kezar Life Sciences, Inc. (NASDAQ: KZR)'s sale to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. If you are a Kezar shareholder, click here to learn more about your legal rights and options.
<div class="lb-trans">Kezar Life Sciences, Inc. (NASDAQ: KZR) 以每股 6.955 美元現金及一項不可轉讓的或有價值權出售給 Aurinia Pharmaceuticals Inc.。如果您是 Kezar 的股東， 請點擊這裏瞭解您的法律權利和選擇。
</div>On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
<div class="lb-trans">代表股東，Halper Sadeh LLC 可能尋求增加對價、額外披露和信息，或其他救濟和利益。
</div>Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
<div class="lb-trans">Halper Sadeh LLC 代表全球的投資者，幫助他們應對證券欺詐和企業不當行為。我們的律師在實施公司改革和為受欺詐投資者追回數百萬美元方面發揮了重要作用。
</div>Attorney Advertising. Prior results do not guarantee a similar outcome.
<div class="lb-trans">律師廣告。以往的結果並不保證類似的結果。
</div>Contact Information:
<div class="lb-trans">聯繫信息：
</div>Halper Sadeh LLC
<div class="lb-trans">Halper Sadeh LLC
</div>Daniel Sadeh, Esq.
<div class="lb-trans">Daniel Sadeh, Esq.
</div>Zachary Halper, Esq.
<div class="lb-trans">Zachary Halper, Esq.
</div>One World Trade Center
<div class="lb-trans">世界貿易中心一號
</div>85th Floor
<div class="lb-trans">85 層
</div>New York, NY 10007
<div class="lb-trans">紐約，NY 10007
</div>(212) 763-0060
<div class="lb-trans">(212) 763-0060
</div>[email protected]
<div class="lb-trans">[email protected]
</div>[email protected]
<div class="lb-trans">[email protected]
</div>https://www.halpersadeh.com
<div class="lb-trans">https://www.halpersadeh.com
</div>SOURCE Halper Sadeh LLP
<div class="lb-trans">來源 Halper Sadeh LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY31660&amp;Transmission_Id=202604101334PR_NEWS_USPR_____NY31660&amp;DateId=20260410"/>

13:34 ETAre APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

prnewswire

醫療業 ETF - SPDR

Kezar Life Sciences

Centessa Pharmaceuticals

2 倍做多納斯達克生物技術 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

Apellis Pharma

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

標普全球醫療股指數 ETF - iShares

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

Apellis Pharma、Centessa Pharmaceuticals、Kezar Life Sciences 是否為其股東爭取到了公平的交易？